Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ASHISH KAMAT and SURENA MATIN.
ASHISH KAMAT
Connection Strength
2.132
SURENA MATIN
  1. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. 2022 10; 40(10):454.e17-454.e23.
    View in: PubMed
    Score: 0.214
  2. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. BJU Int. 2021 11; 128(5):568-574.
    View in: PubMed
    Score: 0.193
  3. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol. 2018 Dec; 36(12):2027-2034.
    View in: PubMed
    Score: 0.160
  4. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. J Endourol. 2017 09; 31(9):946-953.
    View in: PubMed
    Score: 0.151
  5. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014 Jun 15; 120(12):1794-9.
    View in: PubMed
    Score: 0.119
  6. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology. 2011 Jul; 78(1):61-7.
    View in: PubMed
    Score: 0.097
  7. Upper tract urothelial carcinoma: impact of time to surgery. Urol Oncol. 2012 May-Jun; 30(3):266-72.
    View in: PubMed
    Score: 0.094
  8. High-frequency endoluminal ultrasonography as an aid to the staging of upper tract urothelial carcinoma: imaging findings and pathologic correlation. J Ultrasound Med. 2010 Sep; 29(9):1277-84.
    View in: PubMed
    Score: 0.093
  9. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer. 2010 Jul 01; 116(13):3127-34.
    View in: PubMed
    Score: 0.092
  10. Initial experience of teaching robot-assisted radical prostatectomy to surgeons-in-training: can training be evaluated and standardized? BJU Int. 2010 Apr; 105(8):1148-54.
    View in: PubMed
    Score: 0.088
  11. Port-site hernias occurring after the use of bladeless radially expanding trocars. Urology. 2010 Mar; 75(3):574-80.
    View in: PubMed
    Score: 0.088
  12. Cardiac history and risk of post-cystectomy cardiac complications. Urology. 2009 Nov; 74(5):1085-9.
    View in: PubMed
    Score: 0.087
  13. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology. 2007 Aug; 70(2):252-6.
    View in: PubMed
    Score: 0.075
  14. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int. 2006 Dec; 98(6):1176-80.
    View in: PubMed
    Score: 0.072
  15. Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology. 2006 Mar; 67(3):518-23.
    View in: PubMed
    Score: 0.068
  16. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620.
    View in: PubMed
    Score: 0.058
  17. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer. 2022 04; 20(2):176-182.
    View in: PubMed
    Score: 0.051
  18. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass. 2022 Jan; 3(1):37-44.
    View in: PubMed
    Score: 0.050
  19. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
    View in: PubMed
    Score: 0.047
  20. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-na?ve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. 2016 05; 69(5):855-62.
    View in: PubMed
    Score: 0.033
  21. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol. 2014 Dec; 142(6):864-71.
    View in: PubMed
    Score: 0.031
  22. Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urol Oncol. 2015 Feb; 33(2):53-64.
    View in: PubMed
    Score: 0.031
  23. Delayed ureterectomy after incomplete nephroureterectomy for upper tract urothelial carcinoma: pathologic findings and outcomes. Int Braz J Urol. 2013 Nov-Dec; 39(6):817-22.
    View in: PubMed
    Score: 0.029
  24. The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. Urol Oncol. 2012 Nov-Dec; 30(6):821-4.
    View in: PubMed
    Score: 0.024
  25. Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy. Urology. 2010 Dec; 76(6):1419-24.
    View in: PubMed
    Score: 0.023
  26. Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria. J Urol. 2010 Mar; 183(3):929-34.
    View in: PubMed
    Score: 0.022
  27. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009 Mar 15; 115(6):1224-33.
    View in: PubMed
    Score: 0.021
  28. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.